Precision Focus Target cardiovascular and autoimmune/inflammatory disease spaces with AMPEL's blood-based genomic tests (CardioGENE, LuGENE, NephroGene) as decision-support tools to position them as biomarkers for patient stratification and proactive therapy.

Genomic Platform Leverage AMPEL’s Ampel Genomic Platform to offer contract research, gene expression analytics, and ML-driven biomarker discovery services to contract research organizations and pharma firms seeking precision medicine capabilities.

Clinical Readiness Highlight readiness for clinical adoption and risk-managed development, aligning with pharma sponsors seeking targeted diagnostics to de-risk trials and improve enrollment through patient-specific therapies.

Collaborative Partnerships Pursue partnerships with mid- to large-cap biotech firms and CROs that need integrated data science and clinical insight to accelerate target identification and validation for next-generation therapies.

R&D Expansion Signals Capitalize on recent news of Precision Health Summit participation and new blood tests to propose joint development programs, co-marketing efforts, and funded feasibility studies that expand AMPEL’s market reach.